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Abstract
Persistent hepatitis B viral (HBV) infection results in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC).
Recent studies in animal models of viral infection indicate that the interaction between the inhibitory receptor,
programmed death (PD)-1, on lymphocytes and its ligand (PD-L1) play a critical role in T-cell exhaustion by inducing T-cell
inactivation. High PD-1 expression levels by peripheral T-lymphocytes and the possibility of improving T-cell function by
blocking PD-1-mediated signaling confirm the importance of this inhibitory pathway in inducing T-cell exhaustion. We
studied T-cell exhaustion and the effects of PD-1 and PD-L1 blockade on intrahepatic infiltrating T-cells in our recently
developed mouse model of HBV persistence. In this mouse animal model, we demonstrated that there were increased
intrahepatic PD-1-expressing CD8+ and CD4+ T cells in mice with HBV persistence, but PD-1 upregulation was resolved in
mice which had cleared HBV. The Intrahepatic CD8+ T-cells expressed higher levels of PD-1 and lower levels of CD127 in
mice with HBV persistence. Blockade of PD-1/PD-L1 interactions increased HBcAg-specific interferon (IFN)-c production in
intrahepatic T lymphocytes. Furthermore, blocking the interaction of PD-1 with PD-L1 by an anti-PD-1 monoclonal antibody
(mAb) reversed the exhausted phenotype in intrahepatic T lymphocytes and viral persistence to clearance of HBV in vivo.
Our results indicated that PD-1 blockage reverses immune dysfunction and viral persistence of HBV infection in a mouse
animal model, suggesting that the anti-PD-1 mAb might be a good therapeutic candidate for chronic HBV infection.
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Introduction
Hepatitis B virus (HBV) causes acute and chronic inflammatory
liver diseases and subsequent hepatic cirrhosis and hepatocellular
carcinoma (HCC). During chronic HBV infection, a dynamic
balance between viral replication and the host immune response is
pivotal to the pathogenesis of liver disease. It is widely accepted
that adaptive immune responses, particularly cellular immune
responses, mediate the clearance of HBV [1,2] Unfortunately,
HBV-specific T-cell function is impaired in patients with chronic
HBV infection characterized by low levels of antiviral cytokines,
impaired cytotoxic T lymphocyte activity, and persistent viremia
[3]. However, the mechanism underlying this T-cell malfunction
in chronic HBV infection is not completely understood.
The immunologic receptor, programmed death (PD)-1, a 55-
kDa transmembrane protein containing an immunologic receptor
tyrosine-based inhibitory motif, was originally isolated from a T-
cell line exhibiting a high sensitivity to apoptosis [4]. The PD-1/
PD-L1 pathway is well documented to play a negative role in
regulating activation and proliferation of T-cells and production of
cytokines [5,6]. There is evidence that the PD-1 pathway plays an
important role in inhibiting the function of virus-specific CD8+ T-
cells in chronic viral infection involving human immunodeficiency
virus (HIV) [7], hepatitis C virus (HCV) [8], and HBV [9].
Although reports are available on changes in expression levels of
PD-1 and T-cell responses in patients with HBV infection, the
pattern of change of PD-1 expression in the natural course of
chronic HBV infection has not yet been presented.
Recent studies using animal models of viral infection in both
mice and macaques indicated that the interaction between the
inhibitory PD-1 on lymphocytes and its ligand (PD-L1) plays
a critical role in T-cell exhaustion by inducing T-cell inactivation,
and high PD-1 expression levels by peripheral T-lymphocytes and
the possibility of improving T-cell function by blocking PD-1-
mediated signaling confirm the importance of this inhibitory
pathway in inducing T-cell exhaustion [10,11,12]. Moreover, in
vivo manipulation of costimulatory pathways to restore the antiviral
function of exhausted T-cells was successfully applied in mice
persistently infected with a lymphocytic choriomeningitis virus to
improve therapeutic vaccinations [13]. Also, in various human
chronic infections, including hepatitis B, high PD-1 levels are
expressed by virus-specific T-cells, and improved T-cell function
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We recently developed a mouse model of HBV persistence, in
which a single intravenous (i.v.) hydrodynamic injection of HBV
DNA to C57BL/6 mice allows HBV replication and induces
a partial immune response, so that about 40% of the mice carry
HBV for more than 6 months [14]. The model was used to
identify the viral antigen crucial for HBV persistence. Our study
indicated that knocking out HBcAg, but not HBeAg or pol, led to
HBV persistence in mice, and the essential region of HBcAg was
the carboxyl terminus, specifically the 10 terminal amino acids
(HBcAg176,185) [15]. These results indicate that the immune
response triggered in mice by HBcAg during exposure to HBV is
important in determining HBV persistence. Tolerance toward the
HBV surface antigen in this model was shown to be due to
insufficient cellular immunity against the hepatitis B core antigen,
as was documented in humans.
This study was thus undertaken to further define the role of T-
cell exhaustion in chronic HBV infection in a mice animal model,
by comparing the phenotype and function of intrahepatic
infiltrating T lymphocytes in mice with HBV persistence or
HBV clearance, and the effect of PD-1/PD-L1 blockade in
restoring immune dysfunction and clearance of HBV. It is the first
report to demonstrate PD-1/PD-L1 blockade could reverses
immune dysfunction and HBV viral persistence in vivo. This
observation opens new potential perspectives for the development
of novel immunotherapies for chronic hepatitis B.
Materials and Methods
Animals and HBV Constructs
Male C57BL/6 and BALB/c mice were obtained from the
Animal Center of National Taiwan University and maintained
under specific pathogen-free (SPF) conditions. All animal experi-
ments were performed according to regulations approved by the
Animal Ethical Committee of National Taiwan University. The
HBV constructs and pAAV/HBV1.2 mutants were generated by
site-directed mutagenesis as previously described [14,15]. Briefly,
site-directed mutagenesis was used to generate pAAV/HBV1.2
mutants with a QuickChang II site-directed mutagenesis kit
(Stratagene, La Jolla, CA) following the manufacturer’s instruc-
tions. Then, the mutants were amplified by a polymerase chain
reaction (PCR) using pAAV/HBV1.2 as a template.
Hydrodynamic Injection
C57BL/6 mice and BALB/c (male, 6,7 weeks old) were
anesthetized with ketamine and xylazine. Ten micrograms of
HBV plasmid DNA in a volume equivalent to 8% of the mouse
body weight was injected via a tail vein in 5 s. Serum HBsAg,
HBeAg, anti-HBs, and anti-HBc levels were assayed as indicated
to monitor the state of HBV persistence.
Isolation of Intrahepatic Leukocytes
Livers were perfused with 0.2% bovine serum albumin (BSA)/
phosphate-buffered saline (PBS), passed through a nylon mesh,
and digested in collagense-IV and DNase-I (Sigma-Aldrich, St.
Louis, MO) for 30 min. Hepatocytes were removed by centrifu-
gation for 5 min at 100 g and washed with 0.2% BSA/PBS twice
at 500 g for 5 min. Leukocyte subsets were isolated by using
OptiPrepH Density Gradient Medium (Sigma-Aldrich, St. Louis,
MO).
Detection of the HBV Antigen, Antibody (Ab), and DNA
Serum levels of HBsAg, HBeAg, anti-HBc, and anti-HBs Abs
were determined using the AXSYM system kit (Abbott Diag-
nostika, Wiesbaden, Germany). The cutoff value for determining
HBsAg positivity was a signal-to-noise (S/N) ratio of $2 and
a signal-to-cutoff (S/CO) ratio of $1. To detect serum HBV
DNA, each serum sample was pretreated with 25 units of DNase I
(Roche Diagnostics, Mannheim, Germany) at 37uC overnight, and
total DNA was extracted and HBV DNA was detected by a real-
time PCR as previously described [14,15]. Serum alanine
transferase (ALT) was measured on a TBA-200FR automated
clinical chemistry analyzer (Toshiba, Tokyo, Japan) as previously
described [14].
Interferon (IFN)-c Enzyme-linked Immunospot (ELISpot)
Assay
At indicated time points after the hydrodynamic injection, mice
were killed, and splenocytes were cultured and assayed for the
frequencies of antigen-specific IFN-c- secreting cells using an
ELISPOT kit (BD Biosciences, San Jose, CA). Briefly, 10
6
splenocytes were co-cultured with 1 mg/ml of rHBcAg (ID Labs,
London, Canada) in 200 ml RPMI 1640 supplemented with 10%
fetal calf serum (FCS). Cell suspensions were incubated for 20 h.
Spot-forming cells were revealed with a biotin-conjugated
antibody, streptavidin-horseradish peroxidase (HRP) and AEC
substrates (Sigma-Aldrich) and were analyzed using the Immuno-
Spot series 5 analyzer (Cellular Technology Limited, Cleveland,
OH).
Flow Cytometry
For flow cytometry, allophycocyanin (APC)-conjugated anti-
mouse CD3 (BD Biosciences, Palo Alto, CA), phycoerythrin (PE)-
conjugated anti-mouse PD-1, fluorescein isothiocyanate (FITC)-
conjugated CD127, and PE-Cy5.5-conjugated anti-mouse CD4 or
CD8 (BD Biosciences Pharmingen) monoclonal (m)Abs were used
for flow cytometry. For the flow cytometric analysis, 10
5 cells were
labeled in a fluorescence-activated cell sorter (FACS) buffer (PBS/
2% FCS/0.1% sodium azide), fixed in 1% paraformaldehyde
(Sigma-Aldrich, St. Louis, MO) and analyzed on a FACSCalibur
using the CellQuest software (Becton Dickinson, Mountain View,
CA).
In vivo Treatment of Mice with the Anti-PD-1 mAb
An anti mouse PD-1 Ab was purified from hybridoma (clone
G4) culture supernatant (kindly provided by Dr. Lieping Chen,
Yale University). C57BL/6 mice were intraperitoneally (i.p.)
Figure 1. Increased programmed death (PD)-1-expressing CD8+ and CD4+ T-cells in liver-infiltrating lymphocytes from mice with
hepatitis B viral (HBV) persistence. A. C57BL/6 or BALB/c mice were hydrodynamically injected with the pAAV/HBV1.2 plasmid. Four weeks post-
injection, intrahepatic lymphocytes were isolated and PD-1 expression was analyzed by flow cytometry. B and C. C57BL/6 mice were
hydrodynamically injected with pAAV/HBV1.2. Four weeks after hydrodynamic injection, intrahepatic lymphocytes from mice which were HBsAg-
positive (carrier) or HBsAg-negative (cleared) were isolated, and the PD-1 expressions by CD8
+ (B) and CD4
+ (C) T-ells were analyzed by flow
cytometry. The data were representative of at least 12 independent experiments. D. C57BL/6 mice were injected with pAAV/HBV1.2 plasmid
hydrodynamically. HBsAg-positive carrier were sacrificed at 4 weeks post-injection. Intrahepatic lymphocytes and splenocytes were isolated and the
populations of CD4
+PD-1
+ or CD8
+PD-1
+ were determined by flow cytometry analysis. *p,0.05. The data were representative of at least 6
independent experiments.
doi:10.1371/journal.pone.0039179.g001
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hiCD127
low-exhausted phenotype. A and B. HBV core
mutants induced upregulation of PD-1 expression in intrahepatic T lymphocytes. C57BL/6 mice were hydrodynamically injected with WT pAAV/
HBV1.2 or HBV core mutant DNA, including HBV-175 or HBV-38 constructs. Four weeks after the injection, intrahepatic lymphocytes were isolated,
and the PD-1 expressions by CD8
+ (A) and CD4
+ (B) T-cells were analyzed by flow cytometry. C. C57BL/6 mice were hydrodynamically injected with
wild type hepatitis B virus (HBV-wt) and HBV core mutants. Intrahepatic lymphocytes were isolated at 4 weeks, and PD-1 and CD127 expressions by
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administration was initiated every 2 days on day 6 before injection
with the HBV core-truncated (HBV-175) mutant construct.
Thereafter, Abs (200 mg) were repeatedly administered every
3,4 days for a period of 8 weeks.
Results
Increased PD-1-expressing CD8+ and CD4+ T-cells in
Liver-infiltrating Lymphocytes from Mice with HBV
Persistence
Although the chronicity of HBV infection is the result of
impaired HBV-specific immune responses that cannot efficiently
eliminate or cure infected hepatocytes, many issues remain
unsettled. We established a mouse model of HBV persistence in
immunocompetent mice by a hydrodynamic injection of replica-
tion-competent HBV DNA. This approach generated HBV
persistence in C57BL/6 mice, but not in BALB/c mice [14,15].
C57BL/6 and BALB/c mice were hydrodynamically injected with
the pAAV/HBV1.2 plasmid. At the indicated time points,
intrahepatic lymphocytes from mice that were HBsAg-positive
(carrier) or HBsAg-negative (cleared) were isolated, and PD-1
expressions by CD8+ and CD4+ T-cells were analyzed by flow
cytometry. The results in Figure 1 demonstrate that there were
increased proportions of PD1-expressing CD8+ and CD4+ T-cells
in livers of C57BL/6 mice, but not in BALB/c mice. The PD-1
upregulation was not observed in splenic lymphocytes in C57BL/6
mice. Moreover, in C57BL/6 mice, both PD-1-expressing CD8+
and CD4+ intrahepatic T-cells significantly decreased in mice
which had cleared the injected pAAV/HBV1.2 plasmid (cleared
mice), compared to mice with HBV persistence (carrier mice)
(Figure 1). These results indicate a significant increase in PD-1
CD8
+ T cells were analyzed by flow cytometry. D. C57BL/6 mice were hydrodynamically injected with HBV core mutant DNA, HBV-175. Intrahepatic
infiltrating lymphocytes and splenic lymphocytes were isolated at 4 weeks, and PD-1 and CD127 expressions by CD8
+ T cells were analyzed by flow
cytometry. *p,0.05. The data were representative of at least 6 independent experiments.
doi:10.1371/journal.pone.0039179.g002
Figure 3. Impaired HBcAg-specific interferon (IFN)-c T-cell response in C57BL/6 mice with hepatitis B viral (HBV) persistence was
reversed by treatment with anti-PD-1 mAb. C57BL/6 mice were hydrodynamically injected with WT pAAV/HBV1.2 or HBV core mutant DNA,
including HBV-175 or HBV-38 constructs. Ten days after the injection, splenocytes were isolated and HBcAg-specific IFN-c responses were analyzed by
an ELISpot assay. The frequency of HBcAg-specific IFN-c-secreting cells in the presence of an anti-PD-1 or control antibody were measured. Spot-
forming cells per million splenocytes are shown. *p,0.05.
doi:10.1371/journal.pone.0039179.g003
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with HBV persistence. This is consistent with the results of recent
studies of HBV-infected patients, which demonstrated that PD-1
expression can impair virus-specific CD8 T-cell responses during
chronic HBV infection [16,17,18,19,20].
Liver-infiltrating CD8+ Lymphocytes in Carrier Mice
Displayed the PD-1
hiCD127
low-exhausted Phenotype
Furthermore, to further define the role of the HBV core in HBV
persistence in this mice animal model, C57BL/6 mice were
injected with wild-type (WT) pAAV/HBV1.2 or HBV core
mutant DNA, including HBV-175 or HBV-38 [15], and HBV
persistence and PD-1 expression in liver-infiltrating lymphocytes
were analyzed by flow cytometry. Both the HBV-175 and HBV-38
core-mutant viral constructs caused significant loss of the ability to
raise the host immunity to clear the virus, with increased PD-1-
expressing T-cell infiltration, leading to HBV persistence in mice
(Figure 2), consistent with the observation that the HBV core
protein plays an important role in induction of a host immune
response to HBV [15].
Recent studies in animal models of viral infection indicated that
the interaction between PD-1 on lymphocytes and its ligands plays
a critical role in T-cell exhaustion by inducing T-cell inactivation.
HBV-specific PD-1-positive CD8 cells of patients with chronic
HBV infection also displayed lower levels of the interleukin (IL)-7
receptor, CD127, which was previously described in association
with the exhausted phenotype [9,21]. To define the exhausted
phenotype in the PD-1-expressing intrahepatic T-cells in mice
with HBV persistence, liver-infiltrating CD8+ lymphocytes from
mice hydrodynamically injected with the HBV construct were
evaluated for the expressions of both PD-1 and CD127 by CD8
+
T-cells by flow cytometry (Figure 2). The results demonstrate that
PD-1 was more highly expressed by intrahepatic CD8 cells in mice
with HBsAg persistence. Also, among intrahepatic CD8 popula-
tions, CD127 expression was significantly lower in carrier mice
compared to mice which had cleared HBV. The PD-1
hiCD127
low-
exhausted phenotype was not observed in splenic lymphocytes in
mice with HBsAg persistence. Our results indicate that liver-
infiltrating CD8+ lymphocytes in carrier mice displayed the PD-
1
hiCD127
low-exhausted phenotype.
We then asked whether the PD-1/PD-L1 interaction of
intrahepatic T-cells was associated with the impaired immune
response, resulting in a defective T-cell response to HBV in mice
with HBV persistence after an infection. The HBV core-specific
IFN-c T-cell response in mice hydrodynamically injected with WT
pAAV/HBV1.2 (HBV-wt), HBV-175, or HBV-38 in the presence
and absence of anti-PD-1 mAb treatment were analyzed by an
ELISpot assay. Results in Figure 3 demonstrate that the frequency
of HBcAg-specific IFN-c-secreting cells was significantly reduced
in mice injected with HBV core mutant constructs; however,
impairment of the HBcAg-specific IFN-c response was restored
when treated with the anti-PD-1 mAb. Taken together, our results
indicate that the impaired T-cell response to the HBV core in the
IFN-c ELISpot assay could be restored by treatment with an anti-
PD-1 mAb, indicating that the level of PD-1 expression on
intrahepatic T cells is correlated with the anti-viral T-cell response
in vivo.
Blockade of the PD-1 Pathway by an Anti-PD-1 mAb
Reduced the HBV Persistence Rate in this Mouse Animal
Model
To further define the role of T-cell exhaustion in the
pathogenesis of persistent HBV infection in this mice animal
model, and determine the effect of PD-1/PD-L1 blockade on
restoring immune dysfunction and clearance of HBV, C57BL/6
mice were intraperitoneally treated with an anti-PD-1 blocking
mAb or a control isotype Ab. Ab administration was initiated
every 2 days on day 6 before an injection with the HBV core-
truncated (HBV-175) mutant construct. Thereafter, Abs (200 mg)
were repeatedly administered every 3,4 days for a period of 8
weeks. The HBsAg level in mice serum was determined by an
ELISA. The results in Figure 4 demonstrated that blocking the
interaction of PD-1/PD-L1 by the anti-PD-1 mAb significantly
reduced the frequency of HBV persistence in mice injected with
the core-null HBV viral construct, resulting in clearance of HBV in
vivo. The mice treated with anti-PD-1 mAb with higher viral
clearance rate and also showed higher ALT level compared to
control mice. In mice treated with anti-PD-1 mAb, the PD-1
expression level in liver infiltrating lymphocytes after hydrody-
namic infection of HBV was similar to mice treated with control
Ig. In contrast, among intrahepatic CD8 populations, CD127
expression was significantly higher in mice treated anti-PD-1 mAb
compared to mice treated with control Ig (Figure 4), indicating
PD-1 blockage reversed PD-1
hiCD127
low-exhausted phenotype in
intrahepatic CD8+ T cells in mice treated with anti-PD-1 mAb.
Taken together, these results indicate that PD-1 blockage reverses
immune dysfunction as well as the PD-1
hiCD127
low-exhausted
phenotype and viral persistence to HBV infection in this mouse
animal model, suggesting that the anti-PD-1 mAb might be a good
therapeutic candidate for chronic HBV infection.
Discussion
In this study, we demonstrated that there were increased
intrahepatic PD-1-expressing CD8+ and CD4+ T-cells in mice
with HBV persistence. Intrahepatic-infiltrating CD8+ T-cells
expressed higher levels of PD-1 and lower levels of CD127 in
mice with HBV persistence. Furthermore, PD-1/PD-L1 blockade
partially restored the function of intrahepatic T-cells, leading to
viral clearance. Although there were studies with similar observa-
tions from HBV transgenic mice [11] and clinical subjects
[16,19,22], it is the first report to demonstrate PD-1/PD-L1
Figure 4. Blockade of the programmed death (PD)-1 pathway by an anti-PD-1 monoclonal antibody (mAb) reduced the hepatitis B
viral (HBV) persistence rate and reversed PD-1
hiCD127
low-exhausted CD8+ T cells phenotype in a mouse animal model. A. C57BL/6
mice were intraperitoneally treated with an anti-PD-1 blocking mAb or isotype control Ab. Antibody administration was initiated every 2 days on day
6 before being injected with an HBV core-truncated (HBV-175) mutant construct. Thereafter, Abs (200 mg) were repeatedly administered every 3,4
days for a period of 8 weeks. The rates of positive serum HBsAg in the mice receiving anti-PD-1 blocking mAb (N, n=12) were compared with those
in mice receiving isotype control Ab (#, n=11), The HBsAg level in mice serum was determined by an ELISA. HBsAg-positive mice were defined as
having a signal-to-noise (S/N) ratio of $2. B. The ALT levels in the mice receiving anti-PD-1 blocking mAb, isotype control Ab, and untreated. The ALT
level in mice serum was determined by an ELISA. *p,0.05. C and D. Increased CD127 expression and reversed PD-1
hiCD127
low-exhausted CD8+ T cells
phenotype in mice treated with an anti-PD-1 mAb. Intrahepatic lymphocytes from C57BL/6 mice hydrodynamically injected with wild-type (WT)
pAAV/HBV1.2 and HBsAg-positive 4 weeks after the injection were isolated, and the expressions of PD-1 (C) as well as coexpression of PD-1 and
CD127 (D) on CD4+ and CD8+ T cells in the presence of an anti-PD-1 or control antibody were measured by flow cytometry. Serum HBsAg titers were
determined by an ELISA. HBsAg-positive mice were defined as having a signal-to-noise (S/N) ratio of $2. *p,0.05.
doi:10.1371/journal.pone.0039179.g004
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persistence in vivo. Moreover, even though reports are available on
changes in expression levels of PD-1 and T-cell responses in
patients with HBV infection, the pattern of change of PD-1
expression in the course of HBV infection in vivo has not yet been
presented. The results from our study open new potential
perspectives for the development of novel immunotherapies for
chronic hepatitis B.
Our results also demonstrated there were increased PD1-
expressing CD8+ and CD4+ T-cells in mice infected with core
mutants with viral persistence, indicating the HBV core protein, in
particular the terminal 10 amino acids, is critical for inducing
immunity to HBV. In a previous study, we isolated liver-
infiltrating lymphocytes (IHL) from liver tissues of chronic
hepatitis B patients and analyzed their immune phenotype. We
found a significantly increased CD8
+ T-cell population with
increased PD-1 and decreased CD28 [20]. These data are
consistent with the findings in this mouse model and suggest
a tolerant immune response underlying chronic HBV infection in
both humans and mice. Furthermore, the impaired T-cell
response to the HBV core in the IFN-c ELISpot assay was
restored by treatment with the anti-PD-1 mAb (Figure 3),
indicating that PD-1 expression is correlated with the in vivo
antiviral T-cell response. This is consistent with a recent report
that antiviral intrahepatic T-cell responses could be restored by
blocking the PD-1 pathway ex vivo in patients with chronic hepatitis
B infection [22].
Studies in animal models of viral infections show that persistent
exposure to high antigen concentrations can affect the antiviral T-
cell function by causing different degrees of functional impairment,
up to physical T-cell deletion, as a function of the quantity of
antigens to which T-cells are exposed [23]. T-cell exhaustion by
this mechanism may play an important role in the pathogenesis of
HBV-specific T-cell hyporesponsiveness with chronic HBV in-
fection, because high antigen concentrations are consistently
present at all stages of the infection. The importance of T-cell
exhaustion in chronic HBV infection was confirmed by the high
expression of PD-1 by circulating HBV-specific CD8 cells and by
the possibility of partially improving the peripheral blood T-cell
function by blocking the interaction of PD-1/PD-L1 with anti-PD-
L1 Abs [9]. Moreover, additional support for exhaustion is
provided by the inverse correlation between the function of HBV-
specific T-cells and viremia levels, since T-cells are more
profoundly inhibited in the presence of high viremia [9,24].
Because T-cells are an essential component of antiviral protection,
restoration of efficient T-cell function may represent a strategy to
cure infections, and manipulation of costimulatory pathways
involved in T-cell activation may be a rational approach to
achieve this goal. The results obtained in this study that PD-1
blockage reverses immune dysfunction as well as the PD-
1
hiCD127
low-exhausted phenotype, and viral persistence to HBV
infection in this mouse animal model further support this notion.
The outcome of HBV infection, recovery or persistence, is
controlled by the interplay between viral proteins and host factors.
The genetic background of recipients, which correlates with the
strength of immune responses against HBV antigens during
primary activation, also determines the outcome after hydrody-
namic injection. In our results, the CD8+ T cells from BALB/c
mice had significant lower PD-1 expression compared to C57BL/
6 mice. Moreover, in C57BL/6 mice, the PD-1-expressing CD8+
intrahepatic T-cells significantly decreased in mice which had
cleared the injected HBV DNA (cleared mice), compared to mice
with HBV persistence (carrier mice). These results indicate
a significant increase in PD-1 expression in intrahepatic T cells
of mice with HBV persistence. In HBV carrier C57BL/6 mice,
impaired HBcAg-specific immune responses failed to clear HBV
DNA [14]. Yang et al. [25] have observed persistent expression of
HBV antigens in the hepatocytes of immunocompromised mice
after hydrodynamic injection of HBV plasmid DNA. These data
also suggested that impaired immune responses in injected mice
would allow input HBV DNA persistence and increased PD-1
expression in intrahepatic T cells. Our nontransgenic mouse
model for HBV persistence provides opportunities to investigate
the mechanisms and host factors determining HBV persistence.
In conclusion, in this study, we demonstrated that blockade of
the PD-1/PD-L1 interaction increased IFN-c production in
response to the HBV core by intrahepatic lymphocytes. Further-
more, blocking the interaction of PD-1 with its ligand, PD-L1, by
an anti-PD-1 mAb reversed the viral persistence to clearance of
the core-null HBV viral construct in this mouse animal model.
Our results indicate that PD-1 blockage reverses immune
dysfunction and viral persistence to HBV infection in this mouse
animal model, suggesting that anti-PD-1 might be a good
therapeutic candidate for chronic HBV infection.
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